NCT06106282

Breast Cancer Survivors Who Experience Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS)

Breast Cancer Survivors Who Experience Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS): A Multidisciplinary Pain Program Designed to Decrease Pain and Improve Functioning, Mood, and Medication Adherence.

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 105 (actual)
• Sponsor: Mayo Clinic · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study evaluates the effectiveness of a cognitive behavioral multicomponent treatment program in improving pain, mood, and functioning while reducing medication non-adherence in breast cancer patients with Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS).

Detailed description

PRIMARY OBJECTIVES: I. To evaluate the effectiveness of a Multidisciplinary Pain Program for AIMSS, specifically determine the impact of the program on level of pain, functional status, and adherence to prescribed medication. II. To identify predictors of improvement in pain, functional status, and mood following participation in the program. OUTLINE: This is an observational study. Patients attend a 2-day treatment program and complete questionnaires on study. Patients also have their medical records reviewed on study.

Conditions

• Anatomic Stage 0 Breast Cancer AJCC v8
• Anatomic Stage I Breast Cancer AJCC v8
• Anatomic Stage II Breast Cancer AJCC v8
• Anatomic Stage III Breast Cancer AJCC v8
• Hormone Receptor-Positive Breast Carcinoma

Interventions

Type	Name	Description
OTHER	Non-Interventional Study	Non-Interventional Study

Timeline

• Start date: 2023-07-12
• Primary completion: 2025-10-27
• Completion: 2025-10-27
• First posted: 2023-10-30
• Last updated: 2025-10-31

Locations

1 site across 1 country: United States